Rubicon Research to Acquire Neuronasal Stake in $2.5 Million Strategic Deal

Rubicon Research Ltd has signed a stock purchase agreement with U.S.-based Neuronasal Inc. to acquire common shares in tranches, with a total consideration of up to $2.5 million. The move strengthens Rubicon’s pharmaceutical innovation pipeline and signals deeper global expansion in neurology-focused drug delivery.

Stay Ahead – Explore Now! Ambedkar Jayanti: Banks Shut Across Most States Today

STORIES YOU MAY LIKE

Blue Cloud Softech Solutions Ltd Signs $15 Million MoU with Byte Eclipse for Edge AI Chips

Asia’s Biggest Airport Takes Off—But 16,000 Families Must Land Elsewhere

GST 2.0 Rolls Out November 1: Small Businesses to Benefit from 3-Day Auto-Approval System